<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACRPO</journal-id><journal-title-group><journal-title>Asian Case Reports in Oncology</journal-title></journal-title-group><issn pub-type="epub">2169-8821</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACRPO.2015.44006</article-id><article-id pub-id-type="publisher-id">ACRPO-16636</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACRPO20150400000_47032490.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  胃癌根治术后辅助治疗的临床分析
  Clinical Analysis of Postoperative Adjuvant Therapy in Gastric Cancer
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>王</surname><given-names>妹兴</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>肖</surname><given-names>谜</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>蒋</surname><given-names>娉</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>王</surname><given-names>月琴</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>李</surname><given-names>云海</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>复旦大学附属肿瘤医院闵行分院化疗科，上海</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><author-notes><corresp id="cor1">* E-mail:<email>liyunhai@csco.org.cn(李云)</email>;</corresp></author-notes><pub-date pub-type="epub"><day>18</day><month>12</month><year>2015</year></pub-date><volume>04</volume><issue>04</issue><fpage>32</fpage><lpage>38</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
   
   目的：分析胃癌根治术后辅助治疗的疗效和副作用。方法：2005年1月至2012年9月在本院接受综合治疗的患者，男性94例，女性62例，平均年龄58.2岁(23~84岁，中位58岁)。所有病例均为手术病理证实为胃癌，按AJCC分期第7版标准，IA期7例，IB期7例，IIA期6例，IIB期19例，IIIA25例，IIIB期34例，IIIC期44例，IV期12例，不详2例。156例均采用根治性切除。12例术后未行任何化疗，142例术后接受各种方案的化疗，其中64例采用多西紫杉醇 + 铂类 + 氟尿嘧啶类(DCF)或表阿霉素 + 铂类 + 氟尿嘧啶类(ECF)三药方案，66例采用铂类 + 氟尿嘧啶类两药方案，9例采用口服替吉奥或卡培他滨单药化疗，1例仅采用铂类 + 氟尿嘧啶类腹腔灌注，2例化疗方案不详。有28例接受术后放疗。结果：中位随访36.5月。3年总生存率为53.5%，3年局部控制率为82.0%，3年无远处转移率53.8%。单因素分析显示T分期(T1-3或T4)、N分期(N0-1或N2-3)、术后分期(I-II期或III-IV期)与总生存和局部控制有统计学意义，而淋巴管癌浸润(浸润或否)影响远处转移。另外，在术后化疗方面，采用三药方案的在总生存上优于两药方案(P=0.047)。结论：胃癌总体疗效仍不高，术后化疗采用DCF/ECF三药方案OS可能有优势。 Objective: To analyze the response and side effects of postoperative adjuvant therapy in gastric cancer. Methods: From January 2005 to September 2012, 156 patients with gastic cancinoma re-ceived the treatment in our hospital, 94 male, 62 female. The average age is 58.2 years (23 to 84 years, median 58 years). All the cases were pathologically confirmed gastric cancer. According to the 7th edition AJCC staging, IA, 7 cases; IB, 7 cases; IIA, 6 cases; IIB, 19 cases; IIIA, 25 cases; IIIB, 34 cases; IIIC, 44 cases; IV, 12 cases; 2 cases were unknown. All 156 cases have adopted radical resection. 12 cases did not undergo any chemotherapy after surgery; 142 cases received postoperative chemotherapy, 64 cases were treated with docetaxel + platinum + fluorouracil (DCF) or epirubicin + platinum + fluorouracil (ECF) three-drug regimen; 66 cases were treated with platinum + fluorouracil two-drug regimen; 9 cases with oral S1 or capecitabine chemotherapy; one case with only intraperitoneal infusion of platinum + fluorouracil; two cases, unknown chemotherapy regimen. 28 patients received postoperative radiotherapy. Results: The median follow-up was 36.5 months. 3-year overall survival rate was 53.5%; 3-year local control rate was 82.0%; 3-year distant metastasis rate was 53.8%. Univariate analysis showed that T stage (T1-3 or T4), N stage (N0-1 or N2-3), postoperative stage (I-II or III-IV) were statistically significant with local control and overall survival (P &lt; 0.05 for all) and that lymphatic invasion had impact on distant metastasis (P=0.036). In postoperative chemotherapy, the use of three-drug regimen is superior to the two-drug regimen on overall survival (P=0.047). Conclusions: The overall effect of treatment in gastric cancer remains poor. Postoperative chemotherapy using DCF/ECF three-drug regimen might have an advantage on overall survival.
    
  
 
</p></abstract><kwd-group><kwd>胃肿瘤，预后，因素分析，统计学, Stomach Neoplasms</kwd><kwd> Prognosis</kwd><kwd> Factor Analysis</kwd><kwd> Statistical</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>胃癌根治术后辅助治疗的临床分析<sup> </sup></title><p>王妹兴，肖谜，蒋娉，王月琴，李云海<sup>*</sup></p><p>复旦大学附属肿瘤医院闵行分院化疗科，上海</p><disp-formula id="hanspub.16636-formula249"><graphic xlink:href="http://html.hanspub.org/file/2-2530039x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>收稿日期：2015年12月9日；录用日期：2015年12月26日；发布日期：2015年12月29日</p><disp-formula id="hanspub.16636-formula250"><graphic xlink:href="http://html.hanspub.org/file/2-2530039x8_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s2"><title>摘 要</title><p>目的：分析胃癌根治术后辅助治疗的疗效和副作用。方法：2005年1月至2012年9月在本院接受综合治疗的患者，男性94例，女性62例，平均年龄58.2岁(23~84岁，中位58岁)。所有病例均为手术病理证实为胃癌，按AJCC分期第7版标准，IA期7例，IB期7例，IIA期6例，IIB期19例，IIIA25例，IIIB期34例，IIIC期44例，IV期12例，不详2例。156例均采用根治性切除。12例术后未行任何化疗，142例术后接受各种方案的化疗，其中64例采用多西紫杉醇 + 铂类 + 氟尿嘧啶类(DCF)或表阿霉素 + 铂类 + 氟尿嘧啶类(ECF)三药方案，66例采用铂类 + 氟尿嘧啶类两药方案，9例采用口服替吉奥或卡培他滨单药化疗，1例仅采用铂类 + 氟尿嘧啶类腹腔灌注，2例化疗方案不详。有28例接受术后放疗。结果：中位随访36.5月。3年总生存率为53.5%，3年局部控制率为82.0%，3年无远处转移率53.8%。单因素分析显示T分期(T1-3或T4)、N分期(N0-1或N2-3)、术后分期(I-II期或III-IV期)与总生存和局部控制有统计学意义，而淋巴管癌浸润(浸润或否)影响远处转移。另外，在术后化疗方面，采用三药方案的在总生存上优于两药方案(P = 0.047)。结论：胃癌总体疗效仍不高，术后化疗采用DCF/ECF三药方案OS可能有优势。</p><p>关键词 :胃肿瘤，预后，因素分析，统计学</p><disp-formula id="hanspub.16636-formula251"><graphic xlink:href="http://html.hanspub.org/file/2-2530039x9_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s3"><title>1. 引言</title><p>胃癌是全球最常见的恶性肿瘤之一，居全世界恶性肿瘤死因第4位，平均每年死亡病例约为700,000 [<xref ref-type="bibr" rid="hanspub.16636-ref1">1</xref>] 。在我国胃癌的发病率比其他国家更高，2010年中国疾病控制中心的数据显示无论城市或乡村，胃癌始终占据死因第3位，分别为14.7%和18.7% [<xref ref-type="bibr" rid="hanspub.16636-ref2">2</xref>] 。虽然手术仍是治疗首选，根治性手术(R0切除)是唯一的治愈手段，超过50%~70%的患者会在5年内复发转移，但术后的综合治疗能提高患者的生存率，降低术后的局部复发和远处转移，近年来多项III期随机临床试验已证实胃癌术后化疗明显提高生存率；对于术后放化疗尚存在争议。笔者总结了156例胃癌术后在我院治疗的病例，试图分析其中的影响因素，报道如下。</p></sec><sec id="s4"><title>2. 资料与方法</title><sec id="s4_1"><title>2.1. 资料来源</title><sec id="s4_1_1"><title>2.1.1. 一般资料</title><p>收集自2005年1月至2012年9月在本院接受综合治疗的患者，男性94例，女性62例，平均年龄58.23岁(23~84岁，中位58岁)。</p></sec><sec id="s4_1_2"><title>2.1.2. 纳入标准</title><p>手术方式均为根治性，仅活检或姑息性切除患者剔除。</p></sec><sec id="s4_1_3"><title>2.1.3. 术后病理</title><p>所有病例均为手术病理证实为胃癌，其中腺癌100例，印戒细胞癌或部分印戒细胞癌32例，黏液腺癌或部分黏液腺癌9例，管状腺癌8例，乳头状腺癌3例，神经内分泌癌2例，未分化癌2例。病理分级分别为高分化2例、中分化24例、低分化113例，未分化1例，不详16例(病理分级含两种分化程度，以分化差的一类计数)。病理类型按病灶分布部位为贲门26例，胃窦56例，胃体66例，全胃4例，不详4例。病灶直径最小0.4cm，最大9cm。解剖淋巴结总数中位19枚(范围0~52枚)。术后病理显示淋巴管累及71例，未累及85例；血管累及67例，未累及89例；神经81例，未累及75例。7例患者切缘阳性。</p></sec><sec id="s4_1_4"><title>2.1.4. 术后分期</title><p>按AJCC分期第7版标准，T：T1a 4例，T1b 6例，T2 9例，T3 38例，T4a 92例，T4b 5例，不详2例。N：N0 30例，N1 21例，N2 39例，N3a 47例，N3b 19例。M：M0 144例，M1 12例。IA期7例，IB期7例，IIA期6例，IIB期19例，IIIA25例，IIIB期34例，IIIC期44例，IV期12例，不详2例。</p></sec></sec><sec id="s4_2"><title>2.2. 治疗方法</title><p>156例均采用根治性切除。12例术后未行任何化疗，142例术后接受各种方案的化疗，其中64例采用多西紫杉醇 + 铂类 + 氟尿嘧啶类(DCF)或表阿霉素 + 铂类 + 氟尿嘧啶类(ECF)三药方案，66例采用铂类 + 氟尿嘧啶类两药方案，9例采用口服替吉奥或卡培他滨单药化疗，1例仅采用铂类 + 氟尿嘧啶类腹腔灌注化，2例化疗方案不详。有28例接受术后放疗。</p></sec><sec id="s4_3"><title>2.3. 评价指标</title><p>总生存(overall survival, OS)指从手术之日计算至任何原因死亡的日期或到随诊截止日期。局部控制率(recurrence-free survival, RFS)指从手术之日到局部复发或最后随诊日期或随诊截止日期。无远处转移生存率(distant metastasis-free survival, DMFS)指从手术之日到影像学检查发现远处转移病灶或最后随诊日期或随诊截止日期。</p></sec><sec id="s4_4"><title>2.4. 统计</title><p>采用SPSS13.0统计软件进行分析，生存分析用Kplan-Meier，生存率比较用Log-rank法，以P &lt; 0.05为差异有统计学意义。</p></sec><sec id="s4_5"><title>2.5. 不良反应</title><p>按照美国国立癌症研究所的CTC3.0毒性指标及分级标准。</p></sec></sec><sec id="s5"><title>3. 结果</title><p>1) 随访至2014年12月，中位随访36.5月。有14例失访，随访率91.0%。死亡71例，其中66例死于肿瘤。3年总生存率为53.5%，3年局部控制率为82.0%，3年无远处转移率53.8%。见图1。</p><p>a) 根据性别、年龄(小于等于58岁或大于58岁)、T分期(T1-3或T4)、N分期(N0-1或N2-3)、术后分期(I~II期或III~IV期)、病变部位(贲门、胃体或胃窦)、病理类型(印戒细胞或非印戒细胞)、解剖淋巴结总数(小于等于19枚或大于19枚)、淋巴管癌浸润(浸润或否)、血管癌浸润(浸润或否)、神经癌浸润(浸润</p><p>图1. 156例胃癌的3年总生存率、局控率以及无远处转移率</p><p>或否)、化疗方式(两药方案或三药方案)进行单因素分析。单因素分析显示T分期(T1-3或T4)、N分期(N0-1或N2-3)、术后分期(I~II期或III~IV期)与总生存和局部控制有统计学意义，而淋巴管癌浸润(浸润或否)影响远处转移。另外，在术后化疗方面，采用三药方案的在总生存上优于两药方案(P = 0.047)。见表1。</p><p>b) 接受术后化疗和或放疗者146例，按CTC3.0急性毒性反应及分级标准：胃肠道毒性反应0级55例，1级46例，2级34例，3级11例；骨髓毒性反应0级60例，1级39例，3级12例，4级7例。</p></sec><sec id="s6"><title>4. 讨论</title><p>胃癌在北美呈下降趋势，但2014年美国预计仍有22,220例胃癌得到诊断，其中10,990例最终将死于肿瘤[<xref ref-type="bibr" rid="hanspub.16636-ref3">3</xref>] 。与欧美的胃癌不同，亚洲的胃癌发病部位主要为非贲门、非食管胃结合部。胃癌在日本仍然是男性第一好发肿瘤，但我国的发病率更高，并且未见下降趋势，预计到2015年发病人数约57.2万，死亡人数达43.4万，而且我国的胃癌诊断时病期往往更晚。目前I期胃癌病人的5年生存率为58%~96%，II期为34%~71%，到IV期仅有7%~17%。总的5年生存率美国为28%，日本为61.4%，我国为40% [<xref ref-type="bibr" rid="hanspub.16636-ref4">4</xref>] ，我们的资料也证实了这一数据。根治性手术(R0切除)是唯一的治愈手段，超过50%~70%的患者会在5年内复发转移，而复发转移后1年生存率很低。因此，胃癌的治疗应该是以手术为主的综合治疗。</p><p>中山大学的詹有庆报道405例胃癌根治性手术患者，其总的5年生存率为43.4%，I、II、III、IV期的患者5年生存率分别为75.6%、58.7%、28.0%、18.4% (P &lt; 0.01)；肿瘤大小&lt;2.0 cm、2.0~3.9 cm、4.0~5.9 cm、6.0~7.9 cm、≥8.0 cm组的患者5年生存率分别为82.0%、57.4%、43.7%、38.7%、26.9% (P &lt; 0.05)；有、无辅加围手术期化疗的患者5年生存率分别为47.2%和37.8%。单因素分析表明围手术期化疗、Borrmann分型、肿瘤大小、组织学类型、pTNM分期是影响胃癌预后的相关因素。多因素分析显示，pTNM分期、肿瘤大小及围手术期化疗是影响胃癌预后的独立因素[<xref ref-type="bibr" rid="hanspub.16636-ref5">5</xref>] 。我们的研究也提示T、N分期是影响胃癌预后，而淋巴管浸润则对远处转移有统计学意义。</p><p>很长一段时期，欧美的胃癌根治术后化疗并没有带来胃癌患者的生存获益，因此颇有争议[<xref ref-type="bibr" rid="hanspub.16636-ref6">6</xref>] -[<xref ref-type="bibr" rid="hanspub.16636-ref10">10</xref>] 。然而，最近亚洲的两项III期随机临床试验显示了胃癌患者D2术后行辅助化疗能明显提高生存率。一项是日本的ACTS-GC研究[<xref ref-type="bibr" rid="hanspub.16636-ref11">11</xref>] ，2001年10月~2004年12月间入选的1059例行根治性切除及D2淋巴结清扫的II~III期胃癌患者，随机口服S-1或安慰剂治疗12月，S-1组和单纯手术组3年总生存率分别为80.1%和70.1%，死亡风险比为0.68(P = 0.003)。这是早期胃癌治疗领域近50年来取得的最重要进步之一，ACTS-GC研究还显示S-1治疗组肿瘤复发风险减少38% (P &lt; 0.0001)。5年的随访更新再次肯定这些数据。另一项则是在韩国、中国大陆、台湾地区37个中心进行的CLASSIC研究[<xref ref-type="bibr" rid="hanspub.16636-ref12">12</xref>] ，入组标准为II~III期胃癌</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Univariate analysis in 156 cases of gastric cance</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >因素</th><th align="center" valign="middle" >例数</th><th align="center" valign="middle" >3年总 生存率(%)</th><th align="center" valign="middle" >Х<sup>2</sup>值</th><th align="center" valign="middle" >P值</th><th align="center" valign="middle" >3年局控率(%)</th><th align="center" valign="middle" >Х<sup>2</sup>值</th><th align="center" valign="middle" >P值</th><th align="center" valign="middle" >3年无远处转移 生存率(%)</th><th align="center" valign="middle" >Х<sup>2</sup>值</th><th align="center" valign="middle" >P值</th></tr></thead><tr><td align="center" valign="middle" >性别</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >男</td><td align="center" valign="middle" >94</td><td align="center" valign="middle" >50.9</td><td align="center" valign="middle" >0.060</td><td align="center" valign="middle" >0.806</td><td align="center" valign="middle" >63.1</td><td align="center" valign="middle" >0.100</td><td align="center" valign="middle" >0.752</td><td align="center" valign="middle" >29.4</td><td align="center" valign="middle" >0.965</td><td align="center" valign="middle" >0.326</td></tr><tr><td align="center" valign="middle" >女</td><td align="center" valign="middle" >62</td><td align="center" valign="middle" >55.0</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >75.0</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >42.0</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >年龄</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >≤58岁</td><td align="center" valign="middle" >79</td><td align="center" valign="middle" >64.8</td><td align="center" valign="middle" >3.209</td><td align="center" valign="middle" >0.073</td><td align="center" valign="middle" >63.2</td><td align="center" valign="middle" >0.908</td><td align="center" valign="middle" >0.341</td><td align="center" valign="middle" >25.6</td><td align="center" valign="middle" >0.129</td><td align="center" valign="middle" >0.719</td></tr><tr><td align="center" valign="middle" >&gt;58岁</td><td align="center" valign="middle" >77</td><td align="center" valign="middle" >58.0</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >61.1</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >42.0</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >T分期</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >T1-3</td><td align="center" valign="middle" >57</td><td align="center" valign="middle" >67.9</td><td align="center" valign="middle" >8.879</td><td align="center" valign="middle" >0.012</td><td align="center" valign="middle" >94.3</td><td align="center" valign="middle" >6.641</td><td align="center" valign="middle" >0.036</td><td align="center" valign="middle" >35.2</td><td align="center" valign="middle" >0.369</td><td align="center" valign="middle" >0.832</td></tr><tr><td align="center" valign="middle" >T4</td><td align="center" valign="middle" >97</td><td align="center" valign="middle" >40.0</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >37.5</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >33.0</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >N分期</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >N0-1</td><td align="center" valign="middle" >51</td><td align="center" valign="middle" >77.6</td><td align="center" valign="middle" >11.365</td><td align="center" valign="middle" >0.001</td><td align="center" valign="middle" >88.6</td><td align="center" valign="middle" >5.972</td><td align="center" valign="middle" >0.015</td><td align="center" valign="middle" >37.2</td><td align="center" valign="middle" >0.000</td><td align="center" valign="middle" >0.995</td></tr><tr><td align="center" valign="middle" >N2-3</td><td align="center" valign="middle" >105</td><td align="center" valign="middle" >40.0</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >42.0</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >31.0</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >术后分期AJCC</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >I~II期</td><td align="center" valign="middle" >39</td><td align="center" valign="middle" >83.3</td><td align="center" valign="middle" >15.216</td><td align="center" valign="middle" >0.000</td><td align="center" valign="middle" >92.2</td><td align="center" valign="middle" >6.941</td><td align="center" valign="middle" >0.031</td><td align="center" valign="middle" >43.0</td><td align="center" valign="middle" >0.403</td><td align="center" valign="middle" >0.817</td></tr><tr><td align="center" valign="middle" >III~IV期</td><td align="center" valign="middle" >115</td><td align="center" valign="middle" >54.0</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >40.0</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >37.0</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >病变部位</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >贲门</td><td align="center" valign="middle" >29</td><td align="center" valign="middle" >57.0</td><td align="center" valign="middle" >3.905</td><td align="center" valign="middle" >0.272</td><td align="center" valign="middle" >78.5</td><td align="center" valign="middle" >2.777</td><td align="center" valign="middle" >0.427</td><td align="center" valign="middle" >31.5</td><td align="center" valign="middle" >1.135</td><td align="center" valign="middle" >0.769</td></tr><tr><td align="center" valign="middle" >胃体</td><td align="center" valign="middle" >64</td><td align="center" valign="middle" >56.7</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >85.4</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >36.5</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >胃窦</td><td align="center" valign="middle" >55</td><td align="center" valign="middle" >50.0</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >47.5</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >31.5</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >病理类型</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >印戒细胞</td><td align="center" valign="middle" >35</td><td align="center" valign="middle" >57.2</td><td align="center" valign="middle" >0.430</td><td align="center" valign="middle" >0.512</td><td align="center" valign="middle" >50.7</td><td align="center" valign="middle" >0.598</td><td align="center" valign="middle" >0.439</td><td align="center" valign="middle" >31.0</td><td align="center" valign="middle" >1.178</td><td align="center" valign="middle" >0.278</td></tr><tr><td align="center" valign="middle" >非印戒细胞</td><td align="center" valign="middle" >121</td><td align="center" valign="middle" >50.0</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >70.0</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >35.0</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >解剖淋巴结总数</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >≤19枚</td><td align="center" valign="middle" >83</td><td align="center" valign="middle" >67.5</td><td align="center" valign="middle" >5.308</td><td align="center" valign="middle" >0.070</td><td align="center" valign="middle" >73.9</td><td align="center" valign="middle" >1.631</td><td align="center" valign="middle" >0.442</td><td align="center" valign="middle" >37.0</td><td align="center" valign="middle" >4.357</td><td align="center" valign="middle" >0.113</td></tr><tr><td align="center" valign="middle" >&gt;19枚</td><td align="center" valign="middle" >67</td><td align="center" valign="middle" >57.5</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >58.0</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >25.0</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >淋巴管</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >癌浸润</td><td align="center" valign="middle" >71</td><td align="center" valign="middle" >58.0</td><td align="center" valign="middle" >0.564</td><td align="center" valign="middle" >0.453</td><td align="center" valign="middle" >50.0</td><td align="center" valign="middle" >1.905</td><td align="center" valign="middle" >0.168</td><td align="center" valign="middle" >20.0</td><td align="center" valign="middle" >4.399</td><td align="center" valign="middle" >0.036</td></tr><tr><td align="center" valign="middle" >否</td><td align="center" valign="middle" >85</td><td align="center" valign="middle" >60.0</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >79.1</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >47.3</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >血管</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >癌浸润</td><td align="center" valign="middle" >67</td><td align="center" valign="middle" >56.0</td><td align="center" valign="middle" >1.515</td><td align="center" valign="middle" >0.218</td><td align="center" valign="middle" >50.0</td><td align="center" valign="middle" >1.222</td><td align="center" valign="middle" >0.269</td><td align="center" valign="middle" >25.0</td><td align="center" valign="middle" >2.896</td><td align="center" valign="middle" >0.089</td></tr><tr><td align="center" valign="middle" >否</td><td align="center" valign="middle" >89</td><td align="center" valign="middle" >60.9</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >78.6</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >43.7</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >神经</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >癌浸润</td><td align="center" valign="middle" >75</td><td align="center" valign="middle" >56.0</td><td align="center" valign="middle" >0.040</td><td align="center" valign="middle" >0.842</td><td align="center" valign="middle" >62.0</td><td align="center" valign="middle" >0.955</td><td align="center" valign="middle" >0.329</td><td align="center" valign="middle" >28.0</td><td align="center" valign="middle" >1.561</td><td align="center" valign="middle" >0.212</td></tr><tr><td align="center" valign="middle" >否</td><td align="center" valign="middle" >81</td><td align="center" valign="middle" >54.8</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >72.0</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >43.6</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >化疗方式</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >两药方案</td><td align="center" valign="middle" >64</td><td align="center" valign="middle" >45.4</td><td align="center" valign="middle" >11.211</td><td align="center" valign="middle" >0.047</td><td align="center" valign="middle" >60.4</td><td align="center" valign="middle" >9.500</td><td align="center" valign="middle" >0.091</td><td align="center" valign="middle" >46.6</td><td align="center" valign="middle" >6.679</td><td align="center" valign="middle" >0.246</td></tr><tr><td align="center" valign="middle" >三药方案</td><td align="center" valign="middle" >66</td><td align="center" valign="middle" >65.0</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >80.0</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >28.0</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr></tbody></table></table-wrap><p>表1. 156例胃癌的单因素分析结果</p><p>患者、D2根治术(至少15枚淋巴结)，1035例随机分为XELOX方案组(每3周的第1天至第14天予以卡培他滨1000 mg/m<sup>2</sup>bid，每3周的第1天予以奥沙利铂130 mg/m<sup>2</sup>，共治疗8个疗程)或观察组，中期分析显示3年DFS为74%，而观察组仅为60%，XELOX方案组的疾病进展风险较观察组下降了44% (P &lt; 0.0001)。在亚组分析中，各组均观察到XELOX方案对3年DFS的益处，总生存率也有优于观察组的趋势。因此在NCCN指南中推荐D2术后的辅助化疗方案为卡培他滨+奥沙利铂或卡培他滨+顺铂，而日本则推荐S-1。</p><p>局部进展的胃癌化疗方案则是以顺铂和氟尿嘧啶类为基础的两药方案和前两者加上另外一种药物的三药方案，目前认为两药毒性较低，三药则适合体能较好的患者。几项前瞻性研究分析了以氟尿嘧啶类为基础的化疗方案，ECF在提高中位生存和改善生活质量方面均占优[<xref ref-type="bibr" rid="hanspub.16636-ref13">13</xref>] [<xref ref-type="bibr" rid="hanspub.16636-ref14">14</xref>] 。而一项前瞻性多中心随机 III 期临床研究——V235则确立了DCF在进展期胃癌的地位[<xref ref-type="bibr" rid="hanspub.16636-ref15">15</xref>] ：在该研究中，445例进展期胃癌患者随机分为DCF或CF两组，中位随访13.6月，无进展时间在DCF组明显长于CF组，分别为5.6月和3.7月(P &lt; 0.001)，中位生存时间DCF组为9.2月，CF组为8.6月(P = 0.02)。随后的瑞士一项 II 期随机临床研究则比较了DCF与ECF，DCF组在总有效率上有占优趋势，但骨髓抑制和感染率也较ECF组增加[<xref ref-type="bibr" rid="hanspub.16636-ref16">16</xref>] 。本组资料的时间跨度为7年，大多数术后化疗为DCF/ECF三药或CF/XELOX两药方案，既显示了指南和循证学依据对国内临床的影响，也反应了在胃癌术后化疗上仍有一定分歧。本研究显示在OS上三药方案较两药方案有优势(P = 0.047)，虽然与报道有相似之处，但考虑到将近一半的患者发生远处转移，后续的化疗更为杂乱，可能还是与采用三药方案的患者体能更好有关。</p><p>在术后放化疗方面，INT-0116研究是标志性研究[<xref ref-type="bibr" rid="hanspub.16636-ref17">17</xref>] 。556例胃癌患者随机分为单纯手术组和术后放化疗组，69%为T3或T4期，85%为淋巴结阳性。中位生存在手术组仅27个月，而术后放化疗组为36个月(P = 0.005)，3年总生存率和无局部失败率(DCF)在术后放化组均有优势(分别为50%：41%和48%：31%)。然而由于INT-0116研究中手术多为D0或D1淋巴结清扫，而在亚洲标准手术为D2淋巴结清扫，因此颇有争议。为此，ARTIST研究着重D2淋巴结清扫术后放化疗的疗效[<xref ref-type="bibr" rid="hanspub.16636-ref18">18</xref>] ，458例随机分为两组，一组为卡培他滨联合顺铂(XP)辅助化疗，另一组则为卡培他滨联合顺铂辅助化疗的基础上行卡培他滨同步放化疗。3年DFS方面，XP组为74.2%，同步放化疗组为78.2% (P = 0.0862)，但在淋巴结阳性亚组中，XP组为72.3%，同步放化疗组为77.5% (P = 0.0365)。因此，NCCN指南仍未对D2根治术后患者推荐同步放化疗。在我们的数据中，仅28例采用术后放疗，且有不少患者因反应而未能坚持同步化疗，还有待以后总结讨论。</p><p>总之，胃癌在我国发病率仍高，而且治疗疗效不高，本组资料属单中心回顾性研究，时间跨度大，影响因素多，其中涉及治疗方面问题颇多，虽然本资料显示三药联合化疗优于两药联合，可能还是与采用三药方案的患者体能更好有关。有待多中心、大规模前瞻性研究确定适合我国的治疗方式。</p></sec><sec id="s7"><title>文章引用</title><p>王妹兴,肖 谜,蒋 娉,王月琴,李云海. 胃癌根治术后辅助治疗的临床分析 Clinical Analysis of Postoperative Adjuvant Therapy in Gastric Cancer[J]. 亚洲肿瘤科病例研究, 2015, 04(04): 32-38. http://dx.doi.org/10.12677/ACRPO.2015.44006</p></sec><sec id="s8"><title>参考文献 (References)</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.16636-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Kamangar, F., Dores, G.M. and Anderson, W.F. (2006) Patterns of Cancer Incidence, Mortality, and Prevalence across Five Continents: Defining Priorities to Reduce Cancer Disparities in Different Geographic Regions of the World. Jour- nal of Clinical Oncology, 24, 2137-2150. &lt;br&gt;http://dx.doi.org/10.1200/JCO.2005.05.2308</mixed-citation></ref><ref id="hanspub.16636-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">陈万青, 张思维, 曾红梅, 等. 中国2010年恶性肿瘤发病与死亡[J]. 中国肿瘤, 2014, 23(1): 1-10.</mixed-citation></ref><ref id="hanspub.16636-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Siegel, R., Ma, J., Zou, Z., et al. (2014) Cancer Statistics, 2014. CA: A Cancer Journal for Clinicians, 64, 9-29. 
&lt;br&gt;http://dx.doi.org/10.3322/caac.21208</mixed-citation></ref><ref id="hanspub.16636-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Hundahl, S.A., Phillips, J.L. and Menck, H.R. (2000) The National Cancer Data Base Report on Poor Survival of US Gastric Carcinoma Patients Treated with Gastrectomy: Fifth Edition American Joint Committee on Cancer stAging, Proximal Disease, and the “Different Disease” Hypothesis. Cancer, 88, 921-932. 
&lt;br&gt;http://dx.doi.org/10.1002/(SICI)1097-0142(20000215)88:4&lt;921::AID-CNCR24&gt;3.0.CO;2-S</mixed-citation></ref><ref id="hanspub.16636-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">詹友庆, 孙晓卫, 李威, 等. 影响根治术后胃癌预后的多因素分析[J]. 癌症, 2005, 24(5): 596-599.</mixed-citation></ref><ref id="hanspub.16636-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Nashimoto, A., Nakajima, T., Furukawa, H., et al. (2003) Randomized Trial of Adjuvant Chemotherapy with Mitomycin, Fluorouracil, and Cytosine Arabinoside Followed by Oral Fluorouracil in Serosa-Negative Gastric Cancer: Japan Clinical Oncology Group 9206-1. Journal of Clinical Oncology, 21, 2282-2287.  
&lt;br&gt;http://dx.doi.org/10.1200/JCO.2003.06.103</mixed-citation></ref><ref id="hanspub.16636-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Bouché, O., Ychou, M., Burtin, P., et al. (2005) Adjuvant Chemotherapy with 5-Fluorouracil and Cisplatin Compared with Surgery Alone for Gastric Cancer: 7-Year Results of the FFCD Randomized Phase III Trial (8801). Annals of Oncology, 16, 1488-1497. &lt;br&gt;http://dx.doi.org/10.1093/annonc/mdi270</mixed-citation></ref><ref id="hanspub.16636-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">De Vita, F., Giuliani, F., Orditura, M., et al. (2007) Adjuvant Chemotherapy with Epirubicin, Leucovorin, 5-Fluorou- racil and Etoposide Regimen in Resected Gastric Cancer Patients: A Randomized Phase III Trial by the Gruppo Oncologico Italia Meridionale (GOIM 9602 Study). Annals of Oncology, 18, 1354-1358.  
&lt;br&gt;http://dx.doi.org/10.1093/annonc/mdm128</mixed-citation></ref><ref id="hanspub.16636-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Di Costanzo, F., Gasperoni, S., Manzione, L., et al. (2008) Adjuvant Chemotherapy in Completely Resected Gastric Cancer: A Randomized Phase III Trial Conducted by GOIRC. Journal of the National Cancer Institute, 100, 388-398.  
&lt;br&gt;http://dx.doi.org/10.1093/jnci/djn054</mixed-citation></ref><ref id="hanspub.16636-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Kulig, J., Kolodziejczyk, P., Sierzega, M., et al. (2010) Adjuvant Chemotherapy with Etoposide, Adriamycin and Cisplatin Compared with Surgery Alone in the Treatment of Gastric Cancer: A Phase III Randomized, Multicenter, Clinical Trial. Oncology, 78, 54-61. &lt;br&gt;http://dx.doi.org/10.1159/000292360</mixed-citation></ref><ref id="hanspub.16636-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Sakuramoto, S., Sasako, M., Yamaguchi, T., et al. (2007) Adjuvant Chemotherapy for Gastric Cancer with S-1, an Oral Fluoropyrimidine. The New England Journal of Medicine, 357, 1810-1820. &lt;br&gt;http://dx.doi.org/10.1056/NEJMoa072252</mixed-citation></ref><ref id="hanspub.16636-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Bang, Y.J., Kim, Y.W., Yang, H.K., et al. (2012) Adjuvant Capecitabine and Oxaliplatin for Gastric Cancer after D2 Gastrectomy (CLASSIC): A Phase 3 Open-Label, Randomised Controlled Trial. Lancet, 379, 315-321.  
&lt;br&gt;http://dx.doi.org/10.1016/S0140-6736(11)61873-4</mixed-citation></ref><ref id="hanspub.16636-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Webb, A., Cunningham, D., Scarffe, J.H., et al. (1997) Randomized Trial Comparing Epirubicin, Cisplatin, and Fluorouracil versus Fluorouracil, Doxorubicin, and Methotrexate in Advanced Esophagogastric Cancer. Journal of Clinical Oncology, 15, 261-267. &lt;br&gt;http://dx.doi.org/10.1016/S0959-8049(97)86090-X</mixed-citation></ref><ref id="hanspub.16636-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Ross, P., Nicolson, M., Cunningham, D., et al. (2002) Prospective Randomized trial Comparing Mitomycin, Cisplatin, and Protracted Venous-Infusion Fluorouracil (PVI 5-FU) with Epirubicin, Cisplatin, and PVI 5-FU in Advanced Esophagogastric Cancer. Journal of Clinical Oncology, 20, 1996-2004. &lt;br&gt;http://dx.doi.org/10.1200/JCO.2002.08.105</mixed-citation></ref><ref id="hanspub.16636-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Van Cutsem, E., Moiseyenko, V.M., Tjulandin, S., et al. (2006) Phase III Study of Docetaxel and Cisplatin plus Fluorouracil Compared with Cisplatin and Fluorouracil as First-Line Therapy for Advanced Gastric Cancer: A Report of the V325 Study Group. Journal of Clinical Oncology, 24, 4991-4997. &lt;br&gt;http://dx.doi.org/10.1200/JCO.2006.06.8429</mixed-citation></ref><ref id="hanspub.16636-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Roth, A.D., Fazio, N., Stupp, R., et al. (2007) Docetaxel, Cisplatin, and Fluorouracil; Docetaxel and Cisplatin; and Epirubicin, Cisplatin, and Fluorouracil as Systemic Treatment for Advanced Gastric Carcinoma: A Randomized Phase II trial of the Swiss Group for Clinical Cancer Research. Journal of Clinical Oncology, 25, 3217-3223.  
&lt;br&gt;http://dx.doi.org/10.1200/JCO.2006.08.0135</mixed-citation></ref><ref id="hanspub.16636-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Macdonald, J.S., Smalley, S.R., Benedetti, J., et al. (2001) Chemoradiotherapy after Surgery Compared with Surgery Alone for Adenocarcinoma of the Stomach or Gastroesophageal Junction. The New England Journal of Medicine, 345, 725-730. &lt;br&gt;http://dx.doi.org/10.1056/NEJMoa010187</mixed-citation></ref><ref id="hanspub.16636-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Lee, J., Lim do, H., Kim, S., et al. (2012) Phase III Trial Comparing Capecitabine plus Cisplatin versus Capecitabine plus Cisplatin with Concurrent Capecitabine Radiotherapy in Completely Resected Gastric Cancer with D2 Lymph Node Dissection: The ARTIST Trial. Journal of Clinical Oncology, 30, 268-273.  
&lt;br&gt;http://dx.doi.org/10.1200/JCO.2011.39.1953</mixed-citation></ref></ref-list></back></article>